Raymond James analyst Jayson Bedford maintained a Buy rating on Edwards Lifesciences on Wednesday, setting a price target of $101, which is approximately 12.69% above the present share price of $89.63.
Bedford expects Edwards Lifesciences to post earnings per share (EPS) of $0.50 for the second quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Moderate Buy rating of shares in Edwards Lifesciences, with an average price target of $97.
The analysts price targets range from a high of $105 to a low of $85.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $1.19 billion and a net profit of $361.2 million. The company's market cap is $55.75 billion.
According to TipRanks.com, Raymond James analyst Jayson Bedford is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 16.8% and a 74.05% success rate.
Incorporated in 1958, California-based Edwards Lifesciences Corp (NYSE:EW). is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.